Deconsolidation of European Subsidiary	6 Months Ended
Jun. 30, 2026
Deconsolidation of European Subsidiary [Abstract]
Deconsolidation of European Subsidiary	2. Deconsolidation of European Subsidiary In April 2026, the Company’s subsidiary, FibroGen Europe Oy (“FibroGen Europe”), voluntarily filed for bankruptcy with the Finnish bankruptcy court. On April 16, 2026, the Helsinki District Court declared FibroGen Europe bankrupt and appointed an estate administrator to oversee the bankruptcy estate. As a result, the Company determined that it no longer maintained a controlling financial interest in FibroGen Europe and therefore deconsolidated the subsidiary effective April 16, 2026 in accordance with ASC 810. The Company determined that the deconsolidation did not represent a strategic shift that has a major effect on its operations and financial results. Accordingly, the results of the subsidiary have not been presented as discontinued operations. FibroGen Europe had product development obligations to the Technology Development Center of the Republic of Finland (“TEKES”), consisting of 11 separate advances received between 1996 and 2008 pursuant to note agreements (the “TEKES Loans”). The advances were granted on a project-by-project basis to fund various product development activities undertaken solely by FibroGen Europe. Kyntra Bio was not a guarantor of the TEKES Loans, and the obligations were non-recourse to Kyntra Bio. Repayment of principal and accrued interest was not required unless FibroGen Europe had distributable funds. FibroGen Europe’s balance sheet before the deconsolidation primarily included $19.2 million of the above-mentioned TEKES Loans, $12.5 million nonredeemable non-controlling interest, and $0.7 million of cumulative foreign currency translation adjustments. Upon deconsolidation, the Company derecognized the subsidiary’s assets and liabilities and recognized a $30.9 million gain on deconsolidation in the condensed consolidated statements of operations for the three and six months ended June 30, 2026. Upon deconsolidation, the Company measured any retained equity interest in FibroGen Europe at fair value in accordance with ASC 810 and determined that the fair value of such retained interest was zero as of April 16, 2026. Following deconsolidation, the Company accounts for any retained equity interest in FibroGen Europe under ASC 321, Investments — Equity Securities. The carrying value of the Company’s retained equity interest in FibroGen Europe remained zero as of June 30, 2026.

Deconsolidation of European Subsidiary

6 Months Ended

Jun. 30, 2026

Deconsolidation of European Subsidiary [Abstract]

2. Deconsolidation of European Subsidiary

In April 2026, the Company’s subsidiary, FibroGen Europe Oy (“FibroGen Europe”), voluntarily filed for bankruptcy with the Finnish bankruptcy court. On April 16, 2026, the Helsinki District Court declared FibroGen Europe bankrupt and appointed an estate administrator to oversee the bankruptcy estate. As a result, the Company determined that it no longer maintained a controlling financial interest in FibroGen Europe and therefore deconsolidated the subsidiary effective April 16, 2026 in accordance with ASC 810. The Company determined that the deconsolidation did not represent a strategic shift that has a major effect on its operations and financial results. Accordingly, the results of the subsidiary have not been presented as discontinued operations.

FibroGen Europe had product development obligations to the Technology Development Center of the Republic of Finland (“TEKES”), consisting of 11 separate advances received between 1996 and 2008 pursuant to note agreements (the “TEKES Loans”). The advances were granted on a project-by-project basis to fund various product development activities undertaken solely by FibroGen Europe. Kyntra Bio was not a guarantor of the TEKES Loans, and the obligations were non-recourse to Kyntra Bio. Repayment of principal and accrued interest was not required unless FibroGen Europe had distributable funds.

FibroGen Europe’s balance sheet before the deconsolidation primarily included $19.2 million of the above-mentioned TEKES Loans, $12.5 million nonredeemable non-controlling interest, and $0.7 million of cumulative foreign currency translation adjustments. Upon deconsolidation, the Company derecognized the subsidiary’s assets and liabilities and recognized a $30.9 million gain on deconsolidation in the condensed consolidated statements of operations for the three and six months ended June 30, 2026.

Upon deconsolidation, the Company measured any retained equity interest in FibroGen Europe at fair value in accordance with ASC 810 and determined that the fair value of such retained interest was zero as of April 16, 2026. Following deconsolidation, the Company accounts for any retained equity interest in FibroGen Europe under ASC 321, Investments — Equity Securities. The carrying value of the Company’s retained equity interest in FibroGen Europe remained zero as of June 30, 2026.